Research / 2019 / Article / Tab 1

Review Article

Promising Results from Alzheimer’s Disease Passive Immunotherapy Support the Development of a Preventive Vaccine

Table 1

Alzheimer’s disease vaccines at the clinical or preclinical stage.

VaccineImmunogenCarrierAdjuvantImmunityStatus

AN1792ANoneQS-21Th1/Th2Terminated
ACC-001ACRM197QS-21Th1/Th2Terminated
Affiris AD02mimic AKLHAlumTh2Terminated
CAD106AVLP§None----Phase 2
V950Aβ N-terminalISCOMATRIXQuil ATh1/Th2Terminated
UB-311ACpG+AlumTh1/Th2Phase 2
ATh epitopesδ-inulin+CpGTh1/Th2Pre-clinical
ABvac40C-term. Aβ40KLHAlumTh2Phase 2
ACI-24ALiposomesMPLATh1/Th2Phase 2
Lu AF20513[A]3Tetanus toxin--------Phase 1
AADvac1Tau-C-KLHAlumTh2Phase 1

(◊) Immunity means the type of immunity induced by the adjuvant, as reported in the literature and not the one described for the vaccine in question. () CRM197 nontoxic diphtheria toxin. () Alum a traditionally assumed Th2 adjuvant has many proinflammatory properties [67, 68]. (§) VLP are virus-like-particles derived from Qβ phage. () UBITh is a proprietary set of T helper epitopes derived from MVT, PT and TT [75]. () MPLA monophosphoryl lipid A.

Please note that the Table of Contents page is currently not displaying content published since June 7, 2021. We are working to fix this issue as soon as possible and apologize for the inconvenience.